THE TREATMENT OF AMEBIASIS WITH FUMAGILLIN
THE TREATMENT OF AMEBIASIS WITH FUMAGILLIN
复制标题
DOI：
10.1126/science.115.2977.71
复制
发表时间：
1952-01-01
期刊：
影响因子：
56.9
通讯作者：
SMITH, RC
中科院分区：
文献类型：
--
作者：
KILLOUGH, JH;MAGILL, GB;SMITH, RC
目前用于治疗阿米巴病的抗生素被认为主要作用于阿米巴必需的细菌伙伴，从而间接影响寄生虫的生存 (1, 2)。最近Hanson和Eble (3)报道了一种新的抗生素——夫马洁林，它几乎没有抗菌和抗真菌活性。 McCowen 等人(4) 随后进行的体外实验和动物研究表明，这种抗生素具有显着的杀阿米巴活性。本说明报告了我们在因感染大群溶组织内阿米巴而住院的青少年和成年男性患者中使用这种抗生素的经验。在该系列治疗的 22 名患者中，12 名无症状，9 名有轻度胃肠道刺激症状，1 名患有严重阿米巴痢疾。 18 名患者口服夫马洁林明胶胶囊 14 天。两名患者每天接受 5 毫克；二，5毫克，每日两次；三、每次10毫克，每日两次；四、每日35毫克，分三次服用；七、每天 50 毫克，分三次服用。另外四名患者接受了 7 天的治疗。一名患者接受 35 毫克剂量，三名患者接受 50 毫克剂量。对每位患者的实验室研究包括频繁的粪便和尿液检查、粪便和尿液培养、全血细胞计数、血尿素氮测定、尿素清除率、心电图以及八项肝功能测试，包括凝血酶原浓度。对四名患者进行了硫代硫酸盐清除，并对一名患者进行了肾静脉插管并进行了对氨基马尿酸和肌酐提取。本研究中使用的任何临床或实验室程序均未显示肝、肾或心血管系统治疗受损的证据。许多患者有血吸虫病引起的肝脏和肾脏受累的证据，但没有一个患者原有的疾病恶化。中毒迹象很少且意义不大。两名每天服用 50 毫克的患者主诉头晕。在一个患者中，当他仍在接受夫马洁林治疗时，这种情况就消退了；而在另一个患者中，这种情况在治疗完成后第二天就消退了。其他四名服用该剂量的患者主诉食欲不振，但没有恶心或呕吐，但在治疗期间没有人体重减轻。溶组织内阿米巴迅速消失
The antibiotics now used in the treatment of ame--biasis are believed to act primarily on the necessary bacterial associates of the amebae, thereby indirectly affecting the survival of the parasite (1, 2). Recently Hanson and Eble (3) have reported a new antibiotic, fumagillin, which has little antibacterial and anti-fungal activity. Subsequent in vitro experiments and animal studies by McCowen et al.(4) have shown this antibiotic to have marked amebicidal activity. The present note reports our experiences with this antibiotic in adolescent and adult male patients who were hospitalized because of infection with the large race of Endamoeba histolytica. Of 22 patients treated in this series, 12 were asymptomatic, nine had symptoms of mild gastrointestinal irritation, and one had severe amebic dysentery. Fumagillin was administered orally in gelatin capsules to 18 patients for 14 days. Two patients received 5 mg daily; two, 5 mg twice daily; three, 10 mg twice daily; four, 35 mg daily in three divided doses; and seven, 50 mg daily in three divided doses. Four other patients were treated for 7 days. One received the 35-mg dosage, and three received the 50-mg dosage.Laboratory studies on each patient consisted of frequent stool and urine examinations, stool and urine cultures, complete blood counts, blood urea nitrogen determinations, urea clearances, electrocardiography, and a battery of eight liver function tests, including prothrombin concentrations. Thiosulfate clearances were done on four patients, and in one patient the renal vein was catheterized and p-aminohippuric acid and creatinine extractions were performed. Evidence of therapeutic impairment of the hepatic, renal, or cardiovascular systems was not revealed by any of the clinical or laboratory procedures used in this study. Many of the patients had evidence of hepatic and renal involvement caused by schistosomiasis, but in none was the pre-existing disease aggravated. Signs of toxicity were few and of little significance. Two patients receiving 50 mg daily complained of dizziness. In one this subsided while he was still receiving fumagillin, and in the other it subsided the day after the completion of therapy. Four other patients at thisdosage complained of a loss of appetite without nausea or vomiting, but none lost weight during the period of treatment. The disappearance of E. histolytica was prompt in